Last update 05 Apr 2025

Placulumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-TNF alpha antibody, Anti-tumour necrosis factor alpha antibody, Placulumab (USAN/INN)
+ [4]
Target
Action
inhibitors
Mechanism
TNF-α inhibitors(Tumor necrosis factor α inhibitors)
Active Indication-
Originator Organization
Active Organization-
Drug Highest PhaseDiscontinuedPhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D10320Placulumab-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Intervertebral Disc DisplacementPhase 2
United States
01 Jan 2011
Intervertebral Disc DisplacementPhase 2
Australia
01 Jan 2011
Radicular PainPhase 2
United States
01 Jan 2011
Radicular PainPhase 2
Australia
01 Jan 2011
SciaticaPhase 2
United States
01 Jan 2011
SciaticaPhase 2
Australia
01 Jan 2011
Rheumatoid ArthritisPhase 2
Sri Lanka
01 Feb 2009
InflammationPhase 2--
InflammationPhase 2--
PsoriasisPhase 2--
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
xddgwdsesb(yzhhyehckr) = jgppmfsfzn okypesyyax (vavazpotox )
-
05 Nov 2019
xcoxwomhwo(jntiojyzea) = tdklazfmxq eqewacqyta (nvulmpuaij )
Not Applicable
-
kpzbdhkpqh(phxoxahhhm) = pdngayxaau yoicuumosm (fsdwggvyqz, (11 - 30))
-
07 May 2017
kpzbdhkpqh(phxoxahhhm) = guyemzlhiz yoicuumosm (fsdwggvyqz, (6 - 20))
Not Applicable
149
(Anti-TNF-naïve UC patients)
cwqowhugvf(dsbexhqizw) = erectdrkef hsliblfylh (uduvggumun )
Positive
12 Feb 2016
Not Applicable
Rheumatoid Arthritis
anti-nuclear antibodies (ANA)
74
caupytddbn(klgueyizcw) = ixcttmyiou imjidstici (zbekzcfods )
Negative
10 Jun 2015
caupytddbn(klgueyizcw) = wkjqfonlln imjidstici (zbekzcfods )
Not Applicable
Behcet Syndrome
TNF alpha | soluble TNF receptors
122
zvkbluwmsm(cgzvjeihzl) = Adverse events were reported in 28% of patients, mainly with infliximab (infliximab 61%, adalimumab 32%; p=0.02). They mainly included infections (52%) and hypersensitivity reactions (16%). Serious adverse events were reported in 13% of patients and required treatment interruption in all cases. dovfnmsvkh (tjltudexab )
Positive
14 Nov 2014
Not Applicable
Behcet Syndrome
TNF alpha | soluble TNF receptors
92
oubohimpis(lallxdvdkv) = Adverse events were reported in 26% of patients, mainly with infliximab. They included infections (19%), hypersensitivity reactions (2%), injection site reactions (2%), cancers (2%) and lupus (1%). Serious adverse events were reported in 8 patients (of whom 7 with infliximab) and required treatment interruption in all cases. vyolyoyzwk (zkujvmrdul )
Positive
11 Jun 2014
Not Applicable
162
jnnlztelfa(hvponpuzfy) = 7% icqehdxiyn (oihifygtpq )
Positive
11 Jun 2014
Not Applicable
Rheumatoid Arthritis
LIGHT | Cathepsin-K | DKK-1 ...
-
dttqjaokih(vedtjfnfde) = ddzbybxkpu djhebrqxwc (siohrwvbvw, 11.3 - 15.3)
-
06 Jun 2012
(Healthy Controls)
dttqjaokih(vedtjfnfde) = twlrsebrwj djhebrqxwc (siohrwvbvw, 45 - 14.3)
Not Applicable
Choroidal Neovascularization
anti-TNF alpha antibody
-
Control (saline injection)
xzadupbefx(wbssdmozvw) = ytwzltvyfp walzjfrojg (aqsaaglyuw )
Positive
01 May 2008
xzadupbefx(wbssdmozvw) = wpbnmfzzac walzjfrojg (aqsaaglyuw, <0.05)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free